Program Announcement

for the

Defense Health Program

Department of Defense

Congressionally Directed Medical Research Programs

Prostate Cancer Research Program

Exploration - Hypothesis Development Award

Funding Opportunity Number: W81XWH-13-PCRP-EHDA

Catalog of Federal Domestic Assistance Number: 12.420

SUBMISSION AND REVIEW DATES AND TIMES

- **Pre-Application Submission Deadline:** 5:00 p.m. Eastern time (ET), July 10, 2013
- **Application Submission Deadline:** 11:59 p.m. ET, July 31, 2013
- **Peer Review:** August 2013
- **Programmatic Review:** November 2013

This Program Announcement is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.

TABLE OF CONTENTS

I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Applications to the Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA). The PCRP was initiated in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY12 totaled $1.21 billion. The FY13 appropriation is $80 million (M).

The mission of the FY13 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

PCRP Overarching Challenges *(revised for FY13)*

Consistent with the program's mission to eliminate death from prostate cancer and enhance the well-being of men experiencing the impact of the disease, including those from disproportionately affected populations, each PCRP funding opportunity either requires or encourages (see Section I.B., Award Information below) applications to address one of the following three PCRP overarching challenges:

- Develop better tools to detect clinically relevant disease in asymptomatic men
- Distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer
- Develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer

PCRP Focus Areas *(revised for FY13)*

All applications for FY13 PCRP funding opportunities are also expected to address at least one of the following PCRP focus areas:

- **Biomarker Development:** Validation and qualification of biomarkers for early detection of clinically relevant disease or for prognosis or prediction and assessment of response to therapies
- **Genetics:** Understanding host or tumor genetics and epigenetics responsible for susceptibility, disease progression, and treatment outcomes for clinically relevant prostate cancer
- **Imaging:** Development of new anatomic, functional, and molecular imaging approaches for the detection and management of clinically relevant prostate cancer

- **Mechanisms of Resistance:** Understanding primary and acquired resistance to therapy
- **Survivorship and Palliative Care:** Improving the quality of life and well-being of prostate cancer patients and their families
- **Therapy:** Identification of new targets, pathways, and therapeutic modalities
- **Tumor and Microenvironment Biology:** Understanding the intrinsic and extrinsic mechanisms contributing to tumor development and the progression of prostate cancer

B. Award Information

The PCRP Exploration - Hypothesis Development Award mechanism was first offered in FY03. Since then, 1,814 Exploration - Hypothesis Development Award applications have been received, and 209 have been recommended for funding.

The Exploration - Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem in prostate cancer. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or initial proof-of-principle of an innovative hypothesis. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. ***Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged.*** However, logical reasoning and a sound scientific rationale for the proposed work must be described.

The PCRP seeks applications from the wide spectrum of basic, population science, translational, and clinical research. ***In addition, applicants are expected to address at least one of the PCRP focus areas and are highly encouraged to address one of the PCRP overarching challenges.*** If the proposed project does not address any of the overarching challenges, the application should include a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care.

Research involving human subjects is encouraged under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are allowed if they are determined to be no greater than minimal risk by the local IRB of record and the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO). Projects involving human subjects or specimens must be exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Additional information on the protection of human subjects and exempt or expedited review status can be found at https://www.bids.tswg.gov/. For definitions and other information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP eReceipt System at https://cdmrp.org/Program_Announcements_and_Forms/.

All investigators applying to FY13 PCRP funding opportunities are encouraged to consider leveraging resources available through the PCRP-funded Prostate Cancer Biorepository Network (PCBN) (http://www.prostatebiorepository.org) and/or the North Carolina - Louisiana Prostate Cancer Project (PCaP) (http://www.ncla-pcap.org) if retrospectively collected human anatomical substances or correlated data are relevant to the proposed studies.

The Congressionally Directed Medical Research Programs (CDMRP) intends that data and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section K.

C. Eligibility Information

- All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible to apply for this award.
- Cost sharing/matching is not an eligibility requirement.
- Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations.
- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

D. Funding

- The maximum period of performance is **1** year.
- The maximum allowable direct costs for the entire period of performance are **$75,000** plus indirect costs.
- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **1** year.
- Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable direct costs. Indirect costs shall be proposed in accordance with the organization's negotiated rate agreement.

Refer to the General Application Instructions, Section II.C.4., for budget regulations and instructions for the Research & Related Budget. ***For all federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in Section II.C.4. of the General Application Instructions.***

In addition, for this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Salary
- Research supplies
- Clinical research costs (for studies exempt or eligible for expedited review only)
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings

The CDMRP expects to allot approximately $3.0M of the $80M FY13 PCRP appropriation to fund approximately 25 Exploration - Hypothesis Development Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of federal funds for this program.

II. SUBMISSION INFORMATION

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt System (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-13-PCRP-EHDA.

B. Pre-Application Submission Content and Form

All pre-application components must be submitted by the PI through the CDMRP eReceipt System (https://cdmrp.org/).

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the preapplication, the PI must contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt System by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- **Application Information – Tab 1**
- **Application Contacts – Tab 2**
- **Collaborators and Conflicts of Interest – Tab 3**

  FY13 PCRP Integration Panel (IP) members should not be involved in any preapplication or application. A list of FY13 PCRP IP members can be found at http://cdmrp.army.mil/pcrp/panels/panel13. For questions related to IP members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

- **Required Files – Tab 4**

  Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review

sessions. ***Note: At this time, eReceipt is unable to read files made with Adobe Acrobat PDFMaker version 9.0 and higher.***

- **Submit Pre-Application – Tab 5**

  This tab ***must*** be completed for the pre-application to be accepted and processed by CDMRP.

- **Other Documents Tab**

  No additional documents are required.

C. Application Submission Content and Form

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

Reviewers will be blinded to the identity of the PI, collaborators, and their organization(s). Due to the blinded nature of the review process, identifying or making references to the PI, collaborators, or their organization(s) in the Project Narrative, Technical and Lay Abstracts, or List of Abbreviations, Acronyms, and Symbols is prohibited and will result in administrative rejection of the application. In addition, the use of "I," "we," "our," "this organization," or similar phrases that refer to the PI, collaborators, or their organization(s) through the references listed will result in administrative rejection of the application.

Although required, the Statement of Work, Research & Related Budget, R & R Subaward Budget Attachment(s) Form (if applicable), biographical sketch and previous/current/pending support, and Project/Performance Site Location(s) Form will not be forwarded for peer or programmatic review. These documents will be used for administrative purposes only.

Grants.gov application package components: For the Exploration - Hypothesis Development Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. **SF 424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

2. **Attachments Form**

   - **Attachment 1: Project Narrative (two-page limit):** Upload as "ProjectNarrative.pdf." The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and will result in administrative withdrawal of the application. ***The Project Narrative will be available for both peer and programmatic review.***

Describe the proposed project in detail using the outline below. ***Do not include URLs or other information that identify the PI, collaborator(s), or their organization(s).***

- **Innovation:** Innovation should be the primary feature of the proposed study. Concisely state how the proposed project represents the exploration of a shift in paradigm, a new line of questioning, or an innovative methodological approach to an important problem in prostate cancer.
- **Relevance to the PCRP Goals:** Briefly describe how the proposed research is responsive to one of the PCRP overarching challenges. If the proposed project does not address one of the overarching challenges, provide a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care. In addition, state how the research is relevant to at least one of the PCRP focus areas.
- **Hypothesis/Rationale/Purpose**: State the rationale for the proposed research. ***The inclusion of preliminary data is strongly discouraged.***
- **Objectives:** State concisely the specific aims and research strategy of the study. ***This award may not be used to conduct clinical trials or studies that are not exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110).***
- **Methods:** Describe the experimental design and methodology. If the methodology is new or unusual, describe it in sufficient detail for evaluation.

- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named "Support.pdf." If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. ***There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested may result in the removal of those items or administrative withdrawal of the application.***
  - References Cited (five-citation limit): List the references cited (including URLs if available) in the project narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). ***To comply with blinded review, do not include URLs that identify the PI, Collaborator(s), or their organization(s). Do not use formatting (e.g., underline, bold, headers, footers) that identifies the PI, collaborator(s), or their organizations(s).***
  - List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols. ***Do not include information that identifies the organization(s) of the PI or collaborator(s).***

- **Attachment 3: Technical Abstract (one-page limit):** Upload as "TechAbs.pdf."

  State the FY13 PCRP overarching challenge and focus area(s) addressed by the proposed research project. Clearly describe the proposed research in one paragraph including the hypothesis to be explored, the objectives, the innovative aspect of the research, and the relevance of the project to the FY13 PCRP mission of eliminating

death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease. ***Do not include information that identifies the organization(s) of the PI or collaborator(s).***

- **Attachment 4: Lay Abstract (one-page limit):** Upload as "LayAbs.pdf."

  State the FY13 PCRP overarching challenge and focus area(s) addressed by the proposed research project. Clearly describe in one paragraph, in a manner readily understood by readers without a background in science or medicine, the scientific objective of the proposed research and its relevance of the project to the PCRP mission of eliminating death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease. Describe the ultimate applicability of the research (e.g., type(s) of patients it will help, clinical applications). Do not duplicate the technical abstract. The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer advocate community. ***Do not include information that identifies the organization(s) of the PI or collaborator(s).***

- **Attachment 5: Statement of Work (SOW) (one-page limit):** Upload as "SOW.pdf." Refer to the General Application Instructions, Section II.C., for detailed information, including guidance on appropriate SOW formats.

  The SOW should not be used to provide additional information about the project not included in the Project Narrative.

3. **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Application Instructions, Section II.C., for detailed information. PI Biographical Sketch (four-page limit): Upload as "Biosketch_LastName.pdf."
   - PI Previous/Current/Pending Support (no page limit): Upload as "Support_LastName.pdf."
   - Key Personnel Biographical Sketches (four-page limit each): Upload as "Biosketch_LastName.pdf."
   - Key Personnel Previous/Current/Pending Support (no page limit): Upload as "Support_LastName.pdf."

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C., for detailed information.
   - Budget Justification (no page limit): Upload as "BudgetJustification.pdf."

5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C., for detailed information.

D. Submission Dates and Times

All submission dates and times are indicated on the title page of this Program Announcement/ Funding Opportunity. Pre-application and application submissions are required. Failure to meet any one of the deadlines will result in application rejection.

E. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a Data Universal Numbering System (DUNS) number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the System for Award Management (SAM) with an "Active" status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Appendix 3, for information on Grants.gov requirements.

III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, U.S. Army Medical Research and Materiel Command, based on technical merit, the relevance to the mission of the DHP) and PCRP, and the specific intent of the award mechanism. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess. ***For this Program Announcement/Funding Opportunity, reviewers at both tiers of review will be blinded to the identity of the PI, collaborators, and their organization(s).***

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a non-disclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.

B. Application Review Criteria

1. **Peer Review:** To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

- **Innovation**
  - To what degree the proposed concept is innovative.
    - Whether the project proposes new paradigms, challenges existing paradigms, or otherwise represents the exploration of a new line of questioning or an innovative methodological approach to an important problem in prostate cancer.
    - To what degree the proposed research represents more than an incremental advance beyond ongoing or published research.
  - Whether the concept is untested (e.g., no preliminary data).
- **Relevance**
  - To what degree the proposed research is relevant and important to eliminating death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.
- **Research Strategy**
  - To what degree the proposed research is supported by a sound scientific rationale.
  - To what degree the experimental design and methodology are appropriate to address the stated objectives.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influenced the review.

2. **Programmatic Review:** To make funding recommendations, the following equally considered criteria are used by programmatic reviewers:
   a. **Ratings and evaluations of the peer reviewers**
   b. **Relevance to the mission of the DHP and FY13 PCRP, as evidenced by the following:**
      - Adherence to the intent of the award mechanism
      - Programmatic relevance in relation to the PCRP overarching challenges and focus areas
      - Relative innovation
      - Program portfolio composition

C. Recipient Qualification

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D. Application Review Dates

All application review dates and times are indicated on the title page of this Program Announcement/Funding Opportunity.

E. Notification of Application Review Results

Each PI and organization will receive notification of the funding recommendation. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

IV. ADMINISTRATIVE ACTIONS

After receipt of applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The PI, collaborators, or their organization(s) are identified or referenced in the Project Narrative, Technical and/or Lay Abstracts, or List of Abbreviations, Acronyms, and Symbols.
- Use of "I," "we," "our," "this organization," or similar phrases that refer to the PI, collaborators, or their organization(s) through the references listed.

B. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, the PI may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section IV.A., Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

C. Withdrawal

The following may result in administrative withdrawal of the application:

- A FY13 PCRP Integration Panel (IP) member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget

preparation, and the development of any supporting document. A list of the FY13 PCRP IP members can be found at http://cdmrp.army.mil/pcrp/panels/panel13.

- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the Research & Related Budget exceed the maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.
- Inclusion of studies that do not qualify for exempt status under Title 32, Code of Federal Regulations, Part 219, Section 101(b) (32 CFR 219.101[b]) or expedited review (32 CFR 219.110 or 21 CFR 56.110).

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2014. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. Administrative and National Policy Requirements

Refer to the General Application Instructions, Appendix 4, Section D, for general information regarding administrative and national policy requirements.

C. Reporting

Refer to the General Application Instructions, Appendix 4, Section E, for general information on reporting requirements.

D. Award Transfers

Refer to the General Application Instructions, Appendix 4, Section F, for general information on organization or PI changes.

VI. AGENCY CONTACTS

A. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through the CDMRP eReceipt System should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@cdmrp.org

B. Grants.gov Contact Center

Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726

Email: support@grants.gov

Sign up on Grants.gov for "send me change notification emails" by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the application package. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

VII. APPLICATION SUBMISSION CHECKLIST

Grants.gov Application Components	Action	Completed
SF-424 (R&R) Application for Federal Assistance Form	Complete form as instructed.	
Attachments Form	Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1. ***Ensure compliance with blinded review.***	
	Upload Supporting Documentation (Support.pdf) as Attachment 2. ***Ensure compliance with blinded review.***	
	Upload Technical Abstract (TechAbs.pdf) as Attachment 3. ***Ensure compliance with blinded review.***	
	Upload the Lay Abstract (LayAbs.pdf) as Attachment 4. ***Ensure compliance with blinded review.***	
	Upload Statement of Work (SOW.pdf) as Attachment 5.	
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.	
	Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.	
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.	
	Attach Previous/Current/Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.	
Research & Related Budget	Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.	
Project/Performance Site Location(s) Form	Complete form as instructed.	
R & R Subaward Budget Attachment(s) Form	Complete form as instructed.	